Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study highlights the use of dermatoscopy as a valuable tool for diagnosing and monitoring alopecia areata, noting that specific hair shaft alterations such as exclamation-mark hairs and black dots are indicators of active disease, while vellus hairs signal early regrowth.

This study found that allergen treatment in alopecia areata mice appeared to alter leukocyte subset distribution and impaired dendritic cell migration, which may affect T-cell activation and hair follicle recovery.

This study found that young male patients with grade III and IV androgenetic alopecia had elevated levels of serum amyloid A3, suggesting a higher risk of developing atherosclerosis compared to those without the condition.

In this study, researchers developed a new topical atraric acid formulation, AA-TF#15, which showed a significantly higher drug penetration and increased hair regrowth in mice compared to minoxidil and finasteride treatments, suggesting its potential effectiveness for treating scalp androgenic alopecia.

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

The authors concluded that some patients clinically diagnosed with telogen effluvium may actually have alopecia areata incognita, suggested by the presence of dystrophic hairs and development of alopecia patches.

This case report describes a 3-year-old boy with atrichia with papular lesions, emphasizing that dermoscopy, showing the 'cluster of stars' appearance, facilitated diagnosis without needing a skin biopsy.

This research focuses on alopecia areata, highlighting the psychological impact, especially of its variant alopecia areata incognita, and provides diagnostic and treatment tips, but does not report specific results.

Medicaid coverage for alopecia areata treatments is inconsistent and often limited.

This review synthesizes current evidence on alopecia areata, detailing its clinical features, pathogenesis, and treatment options, but does not present new clinical results.

This study identified a four-gene loop as a non-invasive biomarker that selectively activates in alopecia areata, providing a precise target for JAK inhibitor treatments.

This study found that OR-101, a selective JAK3/TEK inhibitor, was associated with dose-dependent improvements in hair growth in humanized mice with alopecia areata, suggesting its potential as a treatment option.

This study reports that AhR pathway expression is significantly reduced in lymphocytes of alopecia areata patients, suggesting its potential as a diagnostic marker and therapeutic target.

This case report describes androgenetic alopecia in two young siblings, highlighting its occurrence in children and suggesting a possible familial pattern given their mother's similar condition.

JAK inhibitors improve hair growth in alopecia areata, especially in patchy types.

This review found that oral JAK inhibitors, used off-label in various inflammatory skin disorders, often resulted in rapid and sustained clinical improvements with acceptable safety over several months, although the evidence is drawn from case-based reports.

This case report observed successful hair regrowth with ritlecitinib in a patient with severe alopecia who did not respond to a previous year of baricitinib therapy.

In this study, 755-nm alexandrite laser treatment significantly reduced acne keloidalis nuchae lesions in male patients, improving quality of life and showing low recurrence rates, with temporary hair loss as a reversible complication.

This study observed a significant reduction in the number of hair follicles with a high proportion in catagen or telogen phase, along with visible vertical columns of connective tissue in the histopathologic examination.

In this retrospective study conducted at a trichology clinic, the off-label use of upadacitinib for at least 24 weeks was found to have a promising efficacy and safety profile for treating severe alopecia areata in adolescents.

This study found that Janus kinase inhibitors significantly improve treatment outcomes for complex skin conditions like atopic dermatitis and alopecia areata, but their implementation requires careful safety considerations, including risk assessments for cardiovascular, malignant, and reproductive issues.

This article reviews the mode of action, efficacy, and safety of Janus kinase inhibitors in autoimmune dermatological conditions but reports no new clinical results.

In this phase 3 trial, baricitinib showed effectiveness and safety in both adolescents and adults with severe alopecia areata, with adolescents achieving higher response rates despite more severe baseline conditions, suggesting the advantages of early treatment.

This study found that cyclosporine A's enhancement of hair growth in mice is partly due to its ability to block the nuclear translocation of apoptosis-inducing factor, slowing the hair follicle transition to the catagen phase.

This report presents a rare case of diffuse hair loss resembling alopecia areata, following a tick bite on the scalp.

This meta-analysis suggests that combining Kang-ai injection with platinum-based chemotherapy may improve tumor response, performance status, immune functions, and reduce adverse reactions in patients with advanced non-small cell lung cancer.

This review discusses recent advances in understanding alopecia areata's disease mechanisms and highlights JAK molecules as promising therapeutic targets, but reports no new clinical results; controlled trials are needed.

This study found that topical 5% minoxidil solution is effective and well tolerated for promoting hair growth in Korean men with androgenetic alopecia over 24 weeks.

This review analyzes the mechanism and evidence supporting the approved use of ritlecitinib, a JAK3/TEC kinase inhibitor, for treating severe alopecia areata in patients aged 12 and older, highlighting its role in the changing therapeutic landscape of this immune-mediated disease.